TEL AVIV, Israel--(BUSINESS WIRE)--Feb 9, 2010 - Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ending December 31, 2009. [more]
SAN DIEGO--(BUSINESS WIRE)--Feb 9, 2010 - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced financial results for the three and 12 months ended December 31, 2009, and reviewed business highlights of the fourth quarter of 2009 and early 2010. [more]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 9, 2010 - Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
[more]
SILVER SPRING, Md., Feb. 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will release its fourth quarter and annual 2009 financial results before market open on Tuesday, February 16, 2010. [more]
09 February 2010, London, UK and Cambridge, MA: - Antisoma plc (LSE: ASM; USOTC: ATSMY) will be announcing its interim results for the six months ended 31 December 2009 on Thursday 18 February 2010.
[more]
ESPOO, Finland, Feb. 9, 2010--Orion's net sales in 2009 totalled EUR 771.5 million (EUR 710.7 million in 2008), up by 8.5% on the previous year. [more]
Leiden, the Netherlands (February 9, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced its financial results for the fourth quarter and full year of 2009, based on International Financial Reporting Standards (IFRS). These financial results are unaudited. [more]
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb 8, 2010 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2009 and provided guidance for 2010. [more]
WILMINGTON, N.C.--(BUSINESS WIRE)--Feb 8, 2010 - PPD, Inc. (Nasdaq: PPDI) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2009. [more]
SUNNYVALE, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (NASDAQ:PCYC) , a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will report financial results for the second fiscal quarter ended December 31, 2009 after the NASDAQ Market closes on Thursday February 11, 2010. The company will conduct a conference call and an audio webcast at 1:30 p.m. PT on the same day. There will be a short slide presentation accompanying the webcast that can be found by clicking the link below. [more]
CHENGDU, China, Feb. 8 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its second quarter ended December 31, 2009. [more]
EAST BRUNSWICK, N.J., Feb. 8 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2009 following the close of the market on Thursday, February 25, 2010. [more]
MISSISSAUGA, ON, Feb. 8 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported operational and financial results for the second quarter of fiscal 2010, ended December 31, 2009. [more]
Venlo, The Netherlands – 08. February 2010 --- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. [more]
ALBANY, N.Y.--(BUSINESS WIRE)--Feb 8, 2010 - AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ending December 31, 2009. [more]
SAN DIEGO--(BUSINESS WIRE)--Feb 8, 2010 - NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. [more]
TORONTO, Feb. 8 /CNW/ - Amorfix Life Sciences, a company focused on focused on treatments and diagnostics for misfolded protein diseases, today reported its third quarter operating results and provided an update on the Company's diagnostic and therapeutic programs. [more]
SEATTLE, Feb. 8 /PRNewswire-FirstCall/ -- On Thursday, February 11, 2010, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 fourth quarter and year-end achievements and financial results. [more]
ALISO VIEJO, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Monday, February 22, 2010 at 10:00 a.m. EST (7:00 a.m. PST) to discuss results for the 2009 fourth quarter and year. [more]
TORONTO, Feb. 8, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Wednesday, February 10, 2010 at 4:30 P.M. EST to discuss Second Quarter fiscal 2010 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call 1-888-224-8026 (North America), 1- 416-359-1270 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
